Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-transducin repeat-containing protein (BTRC), also known as beta-TrCP1, is a critical F-box protein that serves as the substrate recognition subunit of the SCF (Skp1-Cullin1-F-box) E3 ubiquitin ligase complex [UniProt: P63151]. It plays a pivotal role in cellular homeostasis by mediating the phosphorylation-dependent ubiquitination and subsequent proteasomal degradation of key regulatory proteins, including beta-catenin, IkappaB, and CDC25A [PubMed: 15181464]. Through these interactions, BTRC modulates essential signaling pathways such as Wnt/beta-catenin and NF-kappaB, which govern cell proliferation, survival, and the immune response [NCBI Gene: 8945]. In the context of disease, BTRC is often dysregulated in various malignancies, including colorectal and pancreatic cancers, where it can function as either an oncogene or a tumor suppressor depending on the specific cellular context and the stability of its substrates [PubMed: 24513166]. Furthermore, BTRC is exploited by viruses like HIV-1, which uses its Vpu protein to hijack the ligase and degrade CD4, facilitating viral release [PubMed: 9843217]. Therapeutically, BTRC is being explored as a recruitment module for Proteolysis Targeting Chimeras (PROTACs) to induce the degradation of neo-substrates, although its broad range of natural targets poses challenges for achieving high specificity and minimizing systemic toxicity [PubMed: 32111836].
Substrate recognition and recruitment for SCF-type E3 ubiquitin ligase-mediated polyubiquitination and subsequent 26S proteasomal degradation.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-transducin repeat-containing protein (BTRC).